RxDoctor Payments Data

Donna Eoff

Nurse Practitioner · Orlando, FLNPI 1073017463

Payments from drug & device makers

$4,645in general payments, 2019–2025

Across 117 payments — averaging $39.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Axonics, Inc.$948
  • Sumitomo Pharma America, Inc.$369
  • Astellas Pharma US Inc$348
  • Myriad Genetic Laboratories, Inc.$235
  • Novo Nordisk$212
  • plus $775 from 18 others

What the payments were for

  • Speaking & faculty fees$311%
  • Travel & lodging$1,54033%
  • Food & beverage$2,73459%
  • Education$3397%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,645 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$164,475
Medicare patients
415
Services billed
3,958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron316$277,050
GemtesaVibegron120$117,415
Estradiol255$16,087
Trospium Chloride ErTrospium Chloride36$7,846
Tolterodine Tartrate ErTolterodine Tartrate62$6,126
EstringEstradiol11$5,718
PremarinEstrogens, Conjugated12$5,119
Solifenacin Succinate108$5,036
YuvafemEstradiol46$4,086
Fesoterodine Fumarate ErFesoterodine Fumarate26$3,480
Cephalexin28$1,668
Trimethoprim24$1,224
Methenamine Hippurate12$1,176
Trospium Chloride32$1,055
Cefdinir70$895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$348$277,050316 claims
Sumitomo Pharma America, Inc.Gemtesa$369$117,415120 claims
PfizerEstring, Premarin$18$10,83723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →